BioCentury | Mar 2, 2021
Management Tracks

Orphazyme hires Amgen’s Bourdon as CEO; plus Tsang joins Ropes & Gray, and updates from Karolinska, Kadmon, Immunicum, InnoCare, Abivax

...director, clinical and regulatory development. Cooper was CMO at Anokion S.A.Swedish dendritic cell therapy company Immunicum AB...
...named Jereon Rovers as CMO. Rovers is managing director and CMO of DCprime B.V., which merged with Immunicum...
...she was previously CMO of Versantis AG. BC Staff Orphazyme A/S Karolinska Development AB Kadmon Holdings Inc. Abivax S.A. InnoCare Pharma Ltd. Immunicum AB Ropes...
BioCentury | Nov 24, 2020
Product Development

Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime

...January 2020 was approved as the first-ever treatment for adults with a rare thyroid eye disease.Immunicum...
...– Insulin-like growth factor-1 (IGF-1) receptor Karen Tkach Tuzman Eli Lilly and Co. Eiger BioPharmaceuticals Inc. Halozyme Therapeutics Inc. Schroedinger Inc. Immunicum AB DCprime...
BioCentury | Sep 3, 2020
Management Tracks

Dier joining Ultragenyx as CFO; plus Magenta, Galectin, Immunicum, BrainStorm, Vaccinex

...company as a scientific and business consultant. Lewis was managing director of shareholder services at Uline Inc.Immunicum AB...
BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

...Relations Officer Sun Kim will assume Amitay’s responsibilities until a successor is found. Immuno-oncology company Immunicum AB...
...of strategy at Ovid Therapeutics Inc. (NASDAQ:OVID). Robin Sawka, BioCentury Staff Evox Therapeutics Ltd. BridgeBio Artax Biopharma Inc. Nucleix Ltd. IsoPlexis Corp. Centogene Immunicum AB CohBar...
BioCentury | Aug 29, 2019
Clinical News

Aug. 29 Clinical Quick Takes: Immunicum's off-the-shelf cell therapy misses in Phase II for kidney cancer; plus Acurx and Esperion

...Immunicum's cell therapy misses survival endpoint in Phase II RCC trial Immunicum AB (SSE:IMMU) lost SEK1.46 (14%...
...cell carcinoma. The second primary endpoint of median overall survival has not yet been reached. Immunicum...
...2020 and Feb. 26, 2020, respectively. Sandi Wong, Staff Writer ACX-362E (GLS-362E) bempedoic acid/ezetimibe Ilixadencel (intuvax) Acurx Pharmaceuticals LLC Esperion Therapeutics Inc. Immunicum AB Bacterial...
BioCentury | Feb 2, 2018
Company News

Management tracks: Voyager, Chrono

...effective this year. The cancer and infectious disease company is seeking a replacement. Immuno-oncology company Immunicum AB...
BioCentury | Feb 2, 2018
Financial News

Immunicum moves to NASDAQ Stockholm

...Immuno-oncology company Immunicum AB (SSE:IMMU) said it began trading on NASDAQ Stockholm on Jan. 15. The company...
...on Jan. 15. The company had traded on Stockholm First North. Immunicum AB (SSE:IMMU), Gothenburg, Sweden Chris Lieu Immunicum AB...
BioCentury | Dec 30, 2016
Clinical News

Intuvax: Ph I/II data

...meeting in National Harbor. Immunicum said it added 6 additional first-line patients to the trial. Immunicum AB...
...Group (ECOG) scores, body weight and systemic immunological response Status: Phase I/II data Milestone: NA Alex Himes Intuvax Immunicum AB Society...
BioCentury | Apr 28, 2014
Financial News

Immunicum completes private placement

Immunicum AB (SSE:IMMU), Gothenburg, Sweden Business: Cancer Date completed: 4/2/14 Type: Private placement Raised: SEK56 million ($8.5 million) Shares: 3.5 million Price: SEK16 Shares after offering: 17.3 million WIR Staff cancer...
BioCentury | Sep 2, 2013
Clinical News

Intuvax: Phase I/II data

...Phase I/II trial showed that Intuvax led to an average survival of about 14 months. Immunicum...
...a significant reduction in the number of natural killer (NK) cells in the blood, which Immunicum...
...surrounding healthy kidney tissue, suggesting tumor specificity. Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Sutent. Immunicum AB...
Items per page:
1 - 10 of 11
BioCentury | Mar 2, 2021
Management Tracks

Orphazyme hires Amgen’s Bourdon as CEO; plus Tsang joins Ropes & Gray, and updates from Karolinska, Kadmon, Immunicum, InnoCare, Abivax

...director, clinical and regulatory development. Cooper was CMO at Anokion S.A.Swedish dendritic cell therapy company Immunicum AB...
...named Jereon Rovers as CMO. Rovers is managing director and CMO of DCprime B.V., which merged with Immunicum...
...she was previously CMO of Versantis AG. BC Staff Orphazyme A/S Karolinska Development AB Kadmon Holdings Inc. Abivax S.A. InnoCare Pharma Ltd. Immunicum AB Ropes...
BioCentury | Nov 24, 2020
Product Development

Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime

...January 2020 was approved as the first-ever treatment for adults with a rare thyroid eye disease.Immunicum...
...– Insulin-like growth factor-1 (IGF-1) receptor Karen Tkach Tuzman Eli Lilly and Co. Eiger BioPharmaceuticals Inc. Halozyme Therapeutics Inc. Schroedinger Inc. Immunicum AB DCprime...
BioCentury | Sep 3, 2020
Management Tracks

Dier joining Ultragenyx as CFO; plus Magenta, Galectin, Immunicum, BrainStorm, Vaccinex

...company as a scientific and business consultant. Lewis was managing director of shareholder services at Uline Inc.Immunicum AB...
BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

...Relations Officer Sun Kim will assume Amitay’s responsibilities until a successor is found. Immuno-oncology company Immunicum AB...
...of strategy at Ovid Therapeutics Inc. (NASDAQ:OVID). Robin Sawka, BioCentury Staff Evox Therapeutics Ltd. BridgeBio Artax Biopharma Inc. Nucleix Ltd. IsoPlexis Corp. Centogene Immunicum AB CohBar...
BioCentury | Aug 29, 2019
Clinical News

Aug. 29 Clinical Quick Takes: Immunicum's off-the-shelf cell therapy misses in Phase II for kidney cancer; plus Acurx and Esperion

...Immunicum's cell therapy misses survival endpoint in Phase II RCC trial Immunicum AB (SSE:IMMU) lost SEK1.46 (14%...
...cell carcinoma. The second primary endpoint of median overall survival has not yet been reached. Immunicum...
...2020 and Feb. 26, 2020, respectively. Sandi Wong, Staff Writer ACX-362E (GLS-362E) bempedoic acid/ezetimibe Ilixadencel (intuvax) Acurx Pharmaceuticals LLC Esperion Therapeutics Inc. Immunicum AB Bacterial...
BioCentury | Feb 2, 2018
Company News

Management tracks: Voyager, Chrono

...effective this year. The cancer and infectious disease company is seeking a replacement. Immuno-oncology company Immunicum AB...
BioCentury | Feb 2, 2018
Financial News

Immunicum moves to NASDAQ Stockholm

...Immuno-oncology company Immunicum AB (SSE:IMMU) said it began trading on NASDAQ Stockholm on Jan. 15. The company...
...on Jan. 15. The company had traded on Stockholm First North. Immunicum AB (SSE:IMMU), Gothenburg, Sweden Chris Lieu Immunicum AB...
BioCentury | Dec 30, 2016
Clinical News

Intuvax: Ph I/II data

...meeting in National Harbor. Immunicum said it added 6 additional first-line patients to the trial. Immunicum AB...
...Group (ECOG) scores, body weight and systemic immunological response Status: Phase I/II data Milestone: NA Alex Himes Intuvax Immunicum AB Society...
BioCentury | Apr 28, 2014
Financial News

Immunicum completes private placement

Immunicum AB (SSE:IMMU), Gothenburg, Sweden Business: Cancer Date completed: 4/2/14 Type: Private placement Raised: SEK56 million ($8.5 million) Shares: 3.5 million Price: SEK16 Shares after offering: 17.3 million WIR Staff cancer...
BioCentury | Sep 2, 2013
Clinical News

Intuvax: Phase I/II data

...Phase I/II trial showed that Intuvax led to an average survival of about 14 months. Immunicum...
...a significant reduction in the number of natural killer (NK) cells in the blood, which Immunicum...
...surrounding healthy kidney tissue, suggesting tumor specificity. Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Sutent. Immunicum AB...
Items per page:
1 - 10 of 11